{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:17:56Z","timestamp":1790983076861,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,19]]},"DOI":"10.7759\/cureus.112941","type":"journal-article","created":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T11:17:38Z","timestamp":1784459858000},"source":"Crossref","is-referenced-by-count":1,"title":["Cariprazine and Lithium Overdose: A Case Report"],"prefix":"10.7759","author":[{"given":"Matthew C","family":"Tyler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01797-5","article-title":"Cariprazine, a broad-spectrum antipsychotic for the treatment of schizophrenia: pharmacology, efficacy, and safety","volume":"38","author":"Laszlovszky I","year":"2021","unstructured":"Laszlovszky I, Barab\u00e1ssy \u00c1, N\u00e9meth G. Cariprazine, a broad-spectrum antipsychotic for the treatment of schizophrenia: pharmacology, efficacy, and safety. Adv Ther. 2021, 38:3652-73. 10.1007\/s12325-021-01797-5","journal-title":"Adv Ther"},{"key":"ref2","unstructured":"Therapeutic goods administration (TGA). reagila. (2022). Accessed: March 12, 2025: https:\/\/www.tga.gov.au\/resources\/auspmd\/reagila."},{"key":"ref3","unstructured":"Australian medicines handbook. cariprazine. (2025). Accessed: March 13, 2025: https:\/\/amhonline.amh.net.au.acs.hcn.com.au\/chapters\/psychotropic-drugs\/antipsychotics\/cariprazine."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.759211","article-title":"Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability","volume":"9","author":"Citrome L","year":"2013","unstructured":"Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013, 9:193-206. 10.1517\/17425255.2013.759211","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss B","year":"2010","unstructured":"Kiss B, Horv\u00e1th A, N\u00e9methy Z, et al.. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010, 333:328-40. 10.1124\/jpet.109.160432","journal-title":"J Pharmacol Exp Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12752","article-title":"The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out","volume":"69","author":"Citrome L","year":"2015","unstructured":"Citrome L. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015, 69:1211-20. 10.1111\/ijcp.12752","journal-title":"Int J Clin Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)91639-0","article-title":"Assessment of coma and impaired consciousness: a practical scale","volume":"304","author":"Teesdale J","year":"1974","unstructured":"Teesdale J, Graham B. Assessment of coma and impaired consciousness: a practical scale. Lancet. 1974, 304:81-4. 10.1016\/S0140-6736(74)91639-0","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2022.2163901","article-title":"A descriptive study of aripiprazole, brexpiprazole, and cariprazine exposures in children ages 0 to 5 years reported to United States poison centers","volume":"61","author":"Husak N","year":"2023","unstructured":"Husak N, Laudone TW, Leonard JB. A descriptive study of aripiprazole, brexpiprazole, and cariprazine exposures in children ages 0 to 5 years reported to United States poison centers. Clin Toxicol (Phila). 2023, 61:110-5. 10.1080\/15563650.2022.2163901","journal-title":"Clin Toxicol (Phila)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4084","article-title":"A case series of serious and unexpected adverse drug reactions under treatment with cariprazine","volume":"9","author":"Heck J","year":"2021","unstructured":"Heck J, Seifert J, Stichtenoth DO, et al.. A case series of serious and unexpected adverse drug reactions under treatment with cariprazine. Clin Case Rep. 2021, 9:e04084. 10.1002\/ccr3.4084","journal-title":"Clin Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0494-7","article-title":"Cariprazine: first global approval","volume":"75","author":"McCormack PL","year":"2015","unstructured":"McCormack PL. Cariprazine: first global approval. Drugs. 2015, 75:2035-43. 10.1007\/s40265-015-0494-7","journal-title":"Drugs"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S301225","article-title":"Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase II\/III studies","volume":"17","author":"Barab\u00e1ssy \u00c1","year":"2021","unstructured":"Barab\u00e1ssy \u00c1, Sebe B, Acsai K, Laszlovszky I, Szatm\u00e1ri B, Earley WR, N\u00e9meth G. Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase II\/III studies. Neuropsychiatr Dis Treat. 2021, 17:957-70. 10.2147\/NDT.S301225","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0382-z","article-title":"Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trials","volume":"30","author":"Lao KS","year":"2016","unstructured":"Lao KS, He Y, Wong IC, Besag FM, Chan EW. Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trials. CNS Drugs. 2016, 30:1043-54. 10.1007\/s40263-016-0382-z","journal-title":"CNS Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2012.03.002","article-title":"Toxicology and overdose of atypical antipsychotics","volume":"43","author":"Minns AB","year":"2012","unstructured":"Minns AB, Clark RF. Toxicology and overdose of atypical antipsychotics. J Emerg Med. 2012, 43:906-13. 10.1016\/j.jemermed.2012.03.002","journal-title":"J Emerg Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/482386-cariprazine-and-lithium-overdose-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T11:17:39Z","timestamp":1784459859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/482386-cariprazine-and-lithium-overdose-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.112941","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,19]]}}}